In an unprecedented move, Atai Life Sciences, a global biotech company, has invested a significant amount in Beckley Psytech, a company specializing in psychedelic medicine. This strategic investment marks a monumental step towards the development of rapid-acting psychedelic medicines, signifying a potential paradigm shift in mental health treatment.

In the vast realm of holistic health, energy healing emerges as a beacon of hope for many seeking alternative methods to achieve wellness. It's a journey into the unseen, where the tangible meets the intangible, and where the rhythm of our very essence is tuned to its optimal frequency.

Awakn Life Sciences Corp. , a psychedelic biotechnology company focused on researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder, has announced on June 2nd that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder.